Everything below concerns anti-doping category. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
===== Group D2 – Labile prodrug esters ===== Ciclesonide, cortisone acetate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone valerate, prednicarbate, and tixocortol pivalate.
==== Prognosis and treatment ==== Untreated necrotic pulp may result in further complications, such as infection, fever, swelling, abscesses and bone loss. Two treatment options are available for pulpal necrosis.
For instance, Captopril® (Enalapril), Integrilin® (Eptifibatide) and Aggrastat® (Tirofiban) are drugs based on snake venoms, which have been approved by the FDA. In addition to these approved drugs, many other snake venom components are now involved in preclinical or clinical trials for a variety of therapeutic applications.
=== 1968–1969: Original line-up and In the Court of the Crimson King === The first incarnation of King Crimson—Fripp, Michael Giles, Lake, McDonald, and Sinfield—was formed on 30 November 1968 with rehearsals beginning on 13 January 1969. Sinfield coined the band's name in "a moment of pressured panic". Sinfield had already used the term "crimson king" in a set of lyrics before his involvement with Giles, Giles and Fripp. Sinfield insisted that the name did not refer to Beelzebub, prince of demons, and that a "crimson king" was any ruler during whose reign there were "societal rumblings" and "sort of the dark forces of the world". According to Fripp, King Crimson is a synonym for Beelzebub, which is an anglicised form of the Arabic phrase "B'il Sabab", meaning "the man with an aim", to which he related. At this early point, McDonald was the primary composer, with vital contributions from Fripp and Lake, while Sinfield wrote all the lyrics on his own, and also designed and operated the band's unique stage lighting, being credited with "words and illumination" on the album sleeve. Inspired by the Moody Blues, McDonald suggested the group purchase a Mellotron keyboard, and this became a key component of the early Crimson sound. Sinfield described the original Crimson thus: "If it sounded at all popular, it was out. So it had to be complicated, it had to be more expansive chords, it had to have strange influences. If it sounded, like, too simple, we'd make it more complicated, we'd play it in 7/8 or 5/8, just to show off".
The third main set of standards is that the EU requires that electricity or gas enterprises acquire a licence from member state authorities. There must be legal separation into different entities of owners of networks from retailers, although they can be owned by the same enterprise, to ensure transparency of accounting. Then, different enterprises have rights to access infrastructure of network owners on fair and transparent terms, as a way to ensure different member state networks and supplies can become integrated across the EU. Most EU operators are publicly owned, and the Court of Justice in Netherlands v Essent NV emphatically rejected that there was any violation of EU law on free movement of capital by a Dutch Act requiring electricity and gas distributors to be publicly owned, that system operators could not be connected by ownership to generators, and limited the level of debt. The Court of Justice held a public ownership requirement was justified by 'overriding reasons in the public interest', 'to protect consumers' and for the 'security of energy supply'. It further pointed to the foundational case of Costa v ENEL, where the Court held in 1964 that the treaties do 'not prohibit the creation of any state monopolies' so long as they do not operate commercially and discriminate. The approach of EU law is that even where energy companies are privatised, they still are subject to the same rules as the state on direct effect, because it remains that they are 'providing a public service'.
Sources: en.wikipedia.org
== Diagnosis == While heterotopic bone growth can begin spontaneously in FOP patients, Eastlack, like most patients, first experienced a triggered proliferation due to an illness or injury. When he was three or four years old, in 1937, while playing with his sister Helene, on a local street, a car hit him and injured his leg. He was taken to the hospital where his leg was put in a cast before returning home. The fracture never set properly, and when the cast was removed months later, his leg was painfully swollen with a high amount of inflammation. No further action was taken and shortly after, Eastlack began to experience his first set of abnormal bone growths. His hips and knees had become difficult to move. When he was taken to the hospital with this concern, the doctor took X-rays in which the bony deposits on his thigh muscles were revealed. The doctors were not able to diagnose his condition having seen this, and it continued to progress in the anatomically characteristic manner that FOP does. Eastlack soon suffered flare-ups along his back, neck, and chest. In attempts to diagnose and treat Eastlack's condition, the doctors ordered biopsies and performed a total of 11 surgical procedures to remove excess and heterotopic ossification, such as that on his thigh muscles. However, Eastlack's condition was aggravated by such procedures and the bone plates returned thicker and more predominant. It was 1938, the year after the incident, when he was finally diagnosed with myositis ossificans progressiva, which is now known as fibrodysplasia ossificans progressiva (FOP).
=== Anatomy === Exertional rhabdomyolysis results from damage to the intracellular proteins inside the sarcolemma. Myosin and actin break down in the sarcomeres when ATP is no longer available due to injury to the sarcoplasmic reticulum. Damage to the sarcolemma and sarcoplasmic reticulum from direct trauma or high force production causes a high influx of calcium ions into the muscle fibers increasing calcium permeability. Calcium ions build up in the mitochondria, impairing cellular respiration. The mitochondria are unable to produce enough ATP to power the cell properly. Reduction in ATP production impairs the cells' ability to extract calcium from the muscle cell. The ion imbalance causes calcium-dependent enzymes to activate which break down muscle proteins even further. A high concentration of calcium activates muscle cells, causing the muscle to contract while inhibiting its ability to relax. The increase of sustained muscle contraction leads to oxygen and ATP depletion with prolonged exposure to calcium. The muscle cell membrane pump may become damaged allowing free form myoglobin to leak into the bloodstream.
On 8 December 1991, the remaining leaders of the republics signed the Belavezha Accords which agreed that the USSR would be dissolved and replaced with a Commonwealth of Independent States. On 25 December, President Gorbachev announced his resignation and turned all executive powers over to Yeltsin. The next day the Council of Republics voted to dissolve the Union. Since then, the republics have been governed independently with some reconstituting themselves as liberal parliamentary republics and others, particularly in Central Asia, devolving into highly autocratic states under the leadership of the old Party elite.
MRI for imaging anatomical structures or blood flow do not require contrast agents since the varying properties of the tissues or blood provide natural contrasts. However, for more specific types of imaging, exogenous contrast agents may be given intravenously, orally, or intra-articularly. Most contrast agents are either paramagnetic (e.g.: gadolinium, manganese, europium), and are used to shorten T1 in the tissue they accumulate in, or super-paramagnetic (SPIONs), and are used to shorten T2 and T2* in healthy tissue reducing its signal intensity (negative contrast agents). The most commonly used intravenous contrast agents are based on chelates of gadolinium, which is highly paramagnetic. In general, these agents have proved safer than the iodinated contrast agents used in X-ray radiography or CT. Anaphylactoid reactions are rare, occurring in approx. 0.03–0.1%. Of particular interest is the lower incidence of nephrotoxicity, compared with iodinated agents, when given at usual doses—this has made contrast-enhanced MRI scanning an option for patients with renal impairment, who would otherwise not be able to undergo contrast-enhanced CT. Gadolinium-based contrast reagents are typically octadentate complexes of gadolinium(III). The complex is very stable (log K > 20) so that, in use, the concentration of the un-complexed Gd3+ ions should be below the toxicity limit.
Spaghetti red is a chili-topped spaghetti popular around Joplin, Missouri, and a signature dish at Fred and Red's. Cincinnati chili is a spiced meat sauce used to top spaghetti which is often referred to as chili spaghetti.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.